Close menu




October 14th, 2020 | 11:40 CEST

BioNTech, BIGG, Bitcoin - The traffic lights are green!

  • Investments
Photo credits: pixabay.com

A trend is present when the price of security tends to move in a specific direction, even under fluctuation. To play this trend correctly and to make more significant price gains, one should recognize the signals of a trend reversal. With Bitcoin & Co., this could soon be the case. The stabilization phase is still underway, but buying pressure has increased in the last few days. Companies that have a unique position in the crypto market could benefit from this.

time to read: 2 minutes | Author: Stefan Feulner
ISIN: CA0898041086 , US09075V1026

Table of contents:


    Right on target

    The Mainz-based vaccine company BioNTech can report further positive news. Approximately 1.5 million doses of the Pfizer BioNTech vaccine, one of the most promising candidates in the competition for the first regulatory approval in Europe and the USA, have been ordered by the New Zealand government. According to the government in Wellington, the quantity is sufficient to protect around 750,000 people with double vaccination. Negotiations are also ongoing with other pharmaceutical companies to serve all 5 million residents.

    Bitcoin - Is the second wave coming?

    The world's leading cryptocurrency, which peaked at just under USD 20,000 at the end of 2017, then entered a more substantial correction phase. It fell below the USD 4,000 mark twice, in December 2018, and the Corona low in March 2020, but then recovered with high volatility.

    Since March, digital gold has been steadily moving northwards, with a support zone of over USD 10,000 recently established. If the prices fall below the high reached in August at almost USD 12,500, there will be a reversal of the bull trend, and the chances of attaining the all-time high would be quite realistic. However, if the support level falls below USD 10,000, the scenario mentioned would be invalid.

    Profiteers of the run

    In addition to other crypto-currencies such as Etherum, Ripple or various Altcoins, companies that deal with the topic of crypto-currencies would also benefit disproportionately here. The Canadian Company BIGG Digital Assets Inc. believes that the future of crypto-currencies depends on a secure and regulated environment.

    In this context, the Blockchain Intelligence Group division provides search and analysis tools. The developed product "QLUE" is used by law enforcement agencies, banks, stock exchanges, and ATM operators to conduct due diligence investigations and block the security chain. With greater forensic depth, it examines where the funds in question come from, where they are going, and the profiles of the agencies involved. At the end of September, BIGG was able to convince a federal agency in the United States to use the program. The license runs for one year and costs the agency CAD 320,000.

    Canada's first regulated trading platform

    In the second pillar, Netcoins, a brokerage and stock exchange software is in development to make the buying and selling of cryptocurrency easily accessible to mass consumers and investors, with a focus on compliance and security. Just last month, Netcoins filed for registration with the British Columbia Securities Commission (BCSC) and the Canadian Securities Administrators (CSA), which, if approved, would allow Netcoins to operate the first regulated open-loop crypto-asset trading platform in Canada. For the young Company, this would be a huge milestone.

    Pioneering work offers enormous potential.

    BIGG CEO Mark Binns commented: "BIGG believes the future of crypto is a compliant, safe and regulated environment. It is the basis of existence for our company. Pending this regulatory approval, Netcoins will be the first registered open-loop crypto-trading platform in Canada. This will be a fundamental change for crypto trading in Canada. As individuals and corporations seek to trade crypto assets, they would have a fully legal and registered platform available to them. We also believe this will have a significant positive impact on Netcoins trading volumes in the coming months, being a unique competitive advantage. We look forward to updating our shareholders further with developments in the coming weeks."


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.

    Read

    Commented by André Will-Laudien on September 26th, 2023 | 07:45 CEST

    Artificial Intelligence in Sellout! Nvidia, Defense Metals, ARM Holdings - Nothing works without rare earths!

    • Mining
    • RareEarths
    • AI
    • chips
    • Investments

    After long bull market movements, the stock market usually tends to rotate sectors, or the market enters a general consolidation. In the former case, investors can profit by reallocating their assets while exploring new investment opportunities. In the latter case, all stocks come down, and the capital market generally suffers from a change in sentiment and corrects recently exaggerated valuations. In the case of the new megatrend of Artificial Intelligence (AI), the stock market seems to sense a great need for correction. As if by magic, the blockbuster stock Nvidia rose by 250% in just 9 months. However, it has already retraced nearly 20% from its peak. Where do the opportunities lie for investors?

    Read

    Commented by André Will-Laudien on September 22nd, 2023 | 07:20 CEST

    Recalculation! These are the bare figures: TUI, Saturn Oil + Gas, Deutsche Bank - Buy prices non-stop!

    • Mining
    • Oil
    • travel
    • Investments
    • Banking

    Companies do not always have good figures in their baggage. Analysts listen very carefully to the words of those in charge. Often, it is only a minor sentence that changes entire valuations. TUI is slowly approaching pre-COVID figures. Saturn Oil & Gas must backtrack slightly because of substantial forest fires in Alberta, and Deutsche Bank aims to finalize the Postbank project in 2023. All three stocks offer good buying opportunities because the long-term prospects are quite convincing.

    Read